{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:35:01Z","timestamp":1791470101417,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01665-3","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T14:22:35Z","timestamp":1743690155000},"page":"572-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating the Latest Evidence from Phase III Trials Supporting Treatment Options for De novo Clinically Lymph Node-Positive Hormone-Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3368-5037","authenticated-orcid":false,"given":"Mohamed Ibrahim","family":"Elewaily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"3","key":"1665_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209\u201349.","journal-title":"CA: a cancer journal for clinicians."},{"key":"1665_CR2","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon: International agency for research on cancer. 2020 Nov 25;20182020."},{"issue":"10437","key":"1665_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. 2024;403(10437):1683\u2013722.","journal-title":"The Lancet"},{"key":"1665_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2016.02.014","volume":"96","author":"B Kiss","year":"2016","unstructured":"Kiss B, Thoeny HC, Studer UE. Current status of lymph node imaging in bladder and prostate cancer. Urology. 2016;96:1\u20137.","journal-title":"Urology"},{"issue":"4","key":"1665_CR5","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293\u20137.","journal-title":"Cancer Res"},{"key":"1665_CR6","doi-asserted-by":"crossref","unstructured":"Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. The Lancet. 2000 Apr 29;355(9214):1491-8.","DOI":"10.1016\/S0140-6736(00)02163-2"},{"issue":"2","key":"1665_CR7","first-page":"361","volume":"95","author":"DJ Samson","year":"2002","unstructured":"Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer Interdiscip Int J Am Cancer Soc. 2002;95(2):361\u201376.","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"issue":"14","key":"1665_CR8","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314\u201325.","journal-title":"N Engl J Med"},{"issue":"3","key":"1665_CR9","first-page":"245","volume":"67","author":"MK Buyyounouski","year":"2017","unstructured":"Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW. Prostate cancer\u2013major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: Cancer J Clin. 2017;67(3):245\u201353.","journal-title":"CA: Cancer J Clin"},{"key":"1665_CR10","unstructured":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer (CHAARTED) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Mar 18] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT00309985\/."},{"key":"1665_CR11","unstructured":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Apr 16] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT02799602\/."},{"key":"1665_CR12","unstructured":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Jun 17] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT02677896\/."},{"key":"1665_CR13","unstructured":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (China ARCHES) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Dec 22] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04076059\/."},{"key":"1665_CR14","unstructured":"A Phase III Study for Patients With Metastatic Hormone-na\u00efve Prostate Cancer (PEACE1) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Nov 08] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT01957436\/."},{"key":"1665_CR15","unstructured":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2022 Nov 30] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT02446405\/."},{"key":"1665_CR16","unstructured":"Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer\u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2021 Feb 21] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT00104715\/."},{"issue":"2","key":"1665_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","volume":"66","author":"FC da Silva","year":"2014","unstructured":"da Silva FC, da Silva FM, Goncalves F, Santos A, Kliment J, Whelan P, Oliver T, Antoniou N, Pastidis S, Queimadelos AM, Robertson C. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol. 2014;66(2):232\u20139.","journal-title":"Eur Urol"},{"key":"1665_CR18","unstructured":"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (S1216) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Nov 14] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT01809691\/."},{"key":"1665_CR19","unstructured":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Apr 18] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00268476\/."},{"key":"1665_CR20","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RC, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. European Urology. 2024 Apr 13.","DOI":"10.1016\/j.eururo.2024.03.027"},{"issue":"3","key":"1665_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D\u2019Amico AV, Desai N, Dorff T, Eastham JA. Prostate cancer, version 3.2024: featured updates to the NCCN guidelines. J Nat Compr Cancer Net. 2024;22(3):140\u201350.","journal-title":"J Nat Compr Cancer Net"},{"issue":"3","key":"1665_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","volume":"2","author":"ND James","year":"2016","unstructured":"James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell JM, Schiavone F, Attard G, De Bono JS. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol. 2016;2(3):348\u201357.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1665_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali A, Hoyle A, Haran \u00c1M, Brawley CD, Cook A, Amos C, Calvert J, Douis H, Mason MD, Dearnaley D, Attard G. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(4):555\u201363.","journal-title":"JAMA Oncol"},{"issue":"10323","key":"1665_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The lancet. 2022;399(10323):447\u201360.","journal-title":"The lancet"},{"issue":"9660","key":"1665_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","volume":"373","author":"A Widmark","year":"2009","unstructured":"Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund J\u00c5, Tasdemir I, Hoyer M, Wiklund F, Foss\u00e5 SD. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. The Lancet. 2009;373(9660):301\u20138.","journal-title":"The Lancet"},{"issue":"9809","key":"1665_CR26","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","volume":"378","author":"P Warde","year":"2011","unstructured":"Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet. 2011;378(9809):2104\u201311.","journal-title":"The Lancet"},{"issue":"3","key":"1665_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","volume":"2","author":"E Ventimiglia","year":"2019","unstructured":"Ventimiglia E, Seisen T, Abdollah F, Briganti A, Fonteyne V, James N, Roach M III, Thalmann GN, Touijer K, Chen RC, Cheng L. A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer. Eur Urol Oncol. 2019;2(3):294\u2013301.","journal-title":"Eur Urol Oncol"},{"key":"1665_CR28","unstructured":"COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer\u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Nov 27] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT03241537\/."},{"issue":"37","key":"1665_CR29","first-page":"130","volume":"1","author":"J Murray","year":"2022","unstructured":"Murray J, Cruickshank C, Bird T, Bell P, Braun J, Chuter D, Ferreira MR, Griffin C, Hassan S, Hujairi N, Melcher A. PEARLS\u2013A multicentre phase II\/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and\/or para-aortic lymph nodes at presentation. Clin Transl Rad Oncol. 2022;1(37):130\u20136.","journal-title":"Clin Transl Rad Oncol"},{"issue":"3","key":"1665_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","volume":"73","author":"T Seisen","year":"2018","unstructured":"Seisen T, Vetterlein MW, Karabon P, Jindal T, Sood A, Nocera L, Nguyen PL, Choueiri TK, Trinh QD, Menon M, Abdollah F. Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis. Eur Urol. 2018;73(3):452\u201361.","journal-title":"Eur Urol"},{"issue":"7","key":"1665_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","volume":"16","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787\u201394.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1665_CR32","doi-asserted-by":"publisher","first-page":"pkac043","DOI":"10.1093\/jncics\/pkac043","volume":"6","author":"ND James","year":"2022","unstructured":"James ND, Ingleby FC, Clarke NW, Amos CL, Attard G, Brawley CD, Chowdhury S, Cross W, Dearnaley DP, Gilbert DC, Gillessen S. Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI cancer spectrum. 2022;6(4):pkac043.","journal-title":"JNCI cancer spectrum."},{"key":"1665_CR33","unstructured":"Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Mar 12] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05116475\/."},{"key":"1665_CR34","doi-asserted-by":"crossref","unstructured":"Tilki D, van den Bergh RC, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology. 2024 Apr 29.","DOI":"10.1016\/j.eururo.2024.04.010"},{"issue":"6","key":"1665_CR35","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"8","key":"1665_CR36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"1665_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LM Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LM, Hulshof MC, Vis AN, Zwinderman AH, Twisk JW, Witjes WP, Delaere KP, van Moorselaar RJ, Verhagen PC, van Andel G. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410\u20138.","journal-title":"Eur Urol"},{"issue":"1","key":"1665_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euo.2022.10.002","volume":"6","author":"HA de Barros","year":"2023","unstructured":"de Barros HA, van Beurden I, Droghetti M, Wilthagen EA, \u00d6zman O, Bergman AM, Aluwini S, van Moorselaar RJ, Donswijk ML, van Leeuwen PJ, van der Poel HG. Role of local and\/or metastasis-directed therapy in patients with hormone-sensitive M1a prostate cancer\u2014a systematic review. Eur Urol Oncol. 2023;6(1):16\u201327.","journal-title":"Eur Urol Oncol"},{"issue":"10162","key":"1665_CR39","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AW, Attard G, Chowdhury S, Cross W, Dearnaley DP. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet. 2018;392(10162):2353\u201366.","journal-title":"The Lancet"},{"issue":"6","key":"1665_CR40","doi-asserted-by":"publisher","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","volume":"19","author":"CC Parker","year":"2022","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Ali A, Amos CL, Attard G, Chowdhury S, Cook A, Cross W, Dearnaley DP. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19(6):e1003998.","journal-title":"PLoS Med"},{"key":"1665_CR41","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, McDermott RS, Flechon A, Tombal BF, Supiot S, Berthold DR, Ronchin P, Kacso G. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design."},{"key":"1665_CR42","unstructured":"Sayyid, R. (2023). Asco 2023: Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (MCSPC): Results of peace-1, a phase 3 randomized trial with a 2x2 design, UroToday.[ Last updated: June 2023]. Available at: https:\/\/www.urotoday.com\/conference-highlights\/asco-2023\/asco-2023-prostate-cancer\/144889-asco-2023-prostate-irradiation-in-men-with-de-novo-low-volume-metastatic-castration-sensitive-prostate-cancer-mcspc-results-of-peace-1-a-phase-3-randomized-trial-with-a-2x2-design.html. Accessed: 28 Jul 2024."},{"issue":"2","key":"1665_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149\u201358.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1665_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Souli\u00e9 M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256\u201362.","journal-title":"Eur Urol"},{"issue":"10024","key":"1665_CR45","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, De Bono J. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet. 2016;387(10024):1163\u201377.","journal-title":"The Lancet"},{"issue":"12","key":"1665_CR46","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W. Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992\u20132003.","journal-title":"Ann Oncol"},{"issue":"7","key":"1665_CR47","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K, Gravis G, James ND. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023;24(7):783\u201397.","journal-title":"Lancet Oncol"},{"issue":"32","key":"1665_CR48","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1665_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"1665_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle AP, Ali A, James ND, Cook A, Parker CC, De Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD. Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer. Eur Urol. 2019;76(6):719\u201328.","journal-title":"Eur Urol"},{"key":"1665_CR51","unstructured":"Davis ID, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu S, Reaume MN, Pook DW, Parnis F, North SA, Marx GM. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)."},{"issue":"34","key":"1665_CR52","doi-asserted-by":"publisher","first-page":"S971","DOI":"10.1016\/j.annonc.2023.09.2745","volume":"1","author":"F Zhou","year":"2023","unstructured":"Zhou F, Gongqian Z, Guo H, Hu Z, Zhang X, He D, He Z, Zhang D, Li Y, Kadeerbai H, Liu Y. 1795P China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA)+ androgen deprivation therapy (ADT) vs PBO+ ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Ann Oncol. 2023;1(34):S971.","journal-title":"Ann Oncol"},{"issue":"4","key":"1665_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, De Porre P. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"key":"1665_CR54","doi-asserted-by":"crossref","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Ju\u00e1rez Soto \u00c1, Merseburger AS, \u00d6zg\u00fcro\u011flu M, Uemura H, Ye D. Apalutamide for metastatic, castration-sensitive prostate cancer. New England J Med. 2019 Jul 4;381(1):13\u201324.","DOI":"10.1056\/NEJMoa1903307"},{"issue":"3","key":"1665_CR55","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151(3):422\u201334.","journal-title":"Int J Cancer"},{"issue":"10336","key":"1665_CR56","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d7 2 factorial design. The Lancet. 2022;399(10336):1695\u2013707.","journal-title":"The Lancet"},{"issue":"12","key":"1665_CR57","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino \u00c1, Ye D. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"1665_CR58","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235\u201348.","journal-title":"Ann Oncol"},{"key":"1665_CR59","unstructured":"Naqvi SA, Riaz ZB, Riaz A, Islam M, Siddiqi R, Ikram W, Jafar MA, Singh P, Ravi PK, Riaz IB, Bryce AH. Triplet therapy in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis."},{"key":"1665_CR60","unstructured":"Naqvi SA, Riaz ZB, Riaz A, Islam M, Siddiqi R, Ikram W, Bin Zafar MD, Singh P, Riaz IB, Bryce AH. Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer."},{"issue":"6","key":"1665_CR61","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s10147-024-02485-4","volume":"29","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A, Rajwa P, Kawada T, Bekku K, Laukhtina E, Klemm J, Pradere B, Mori K, Karakiewicz PI, Kimura T, Chlosta P. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis. Int J Clin Oncol. 2024;29(6):716\u201325.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"1665_CR62","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Iaz","year":"2023","unstructured":"Iaz IB, Naqvi SA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA oncology. 2023;9(5):635\u201345.","journal-title":"JAMA oncology."},{"key":"1665_CR63","unstructured":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Apr 25] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04493853\/."},{"key":"1665_CR64","unstructured":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Jun 14] [cited 2024 Jul 12]. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04736199\/."},{"key":"1665_CR65","unstructured":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Apr 24] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04720157\/."},{"key":"1665_CR66","unstructured":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Jun 20] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05884398\/."},{"key":"1665_CR67","unstructured":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Apr 26] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06120491\/."},{"key":"1665_CR68","unstructured":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Mar 20] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06320067\/."},{"key":"1665_CR69","unstructured":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer (METRO) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Dec 05] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04983095\/."},{"key":"1665_CR70","unstructured":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Feb 22] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04821622\/."},{"key":"1665_CR71","unstructured":"Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Apr 05] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06350825\/."},{"key":"1665_CR72","unstructured":"Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Dec 26] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06177015\/."},{"key":"1665_CR73","unstructured":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Aug 14] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03678025\/."},{"key":"1665_CR74","unstructured":"Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2020 Nov 27] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00303784\/."},{"key":"1665_CR75","unstructured":"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (ENZARAD) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Feb 13] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02446444\/."},{"key":"1665_CR76","unstructured":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP) \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2023 Jul 28] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04136353\/."},{"key":"1665_CR77","unstructured":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS \u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Jun 20] [cited 2024 Jul 12]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02531516\/."},{"key":"1665_CR78","unstructured":"Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer\u2013 U.S. National Library of Medicine [Internet] ClinicalTrials.gov. [last update 2024 Nov 25] [cited 2025 Feb 27]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03456843\/."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01665-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:03:14Z","timestamp":1747285394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["1665"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01665-3","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"8 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.GLB COI: Consulting fees for advisory services or speaker bureau from Astellas, AstraZeneca, Amgen, Bayer. Travel, Accommodations for scientific conferences: Merck, Janssen.AT COI: Research funding from Elekta, Varian and Accuray, Honoraria or travel assistance from Elekta, Accuray, Bayer and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}